Viking Therapeutics, Inc.(VKTX)Earnings, Financials & Key RatiosViking Therapeutics, Inc. (VKTX) stock price & volume — 10-year historical chart
Viking Therapeutics, Inc. (VKTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Viking Therapeutics, Inc. (VKTX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $1.37vs $1.01-35.6% | — |
| Q1 2026 | Feb 11, 2026 | $1.38vs $0.89-55.1% | —vs $2M |
| Q4 2025 | Oct 22, 2025 | $0.81vs $0.70-15.7% | — |
| Q3 2025 | Jul 23, 2025 | $0.58vs $0.44-31.8% | — |
Recent stock market news and headlines for Viking Therapeutics, Inc. (VKTX)
Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near term. EyePoint Pharmaceuticals could soon be a key player in a $15 billion global market.
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $36.97, denoting a -2.38% move from the preceding trading day.
Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.
Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss SAN DIEGO, June 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today the initiation of a Phase 1 single ascending dose (SAD) clinical trial of VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA). VK3019 is being developed as a potential treatment option for weight loss.
Key metrics vs top competitors for Viking Therapeutics, Inc. (VKTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $38.71 | $4.49B | -12.13 | — | — | -47.34% | — | |
| $52.95 | $4.77B | -51.41 | — | — | -20.02% | — | |
| $1.89 | $130.73M | -0.89 | — | — | -59.89% | — | |
| $114.76 | $9.37B | -31.10 | -16.72% | -612.17% | -25.02% | — | |
| $54.75 | $3.15B | -22.81 | — | — | -15.14% | — | |
| $69.26 | $6.11B | -33.30 | 254.7% | -3682.61% | -23.33% | — |
Viking Therapeutics, Inc. (VKTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Viking Therapeutics, Inc. (VKTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 29, 2026·SEC
Feb 11, 2026·SEC
Oct 22, 2025·SEC
Get notified when VKTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Viking Therapeutics, Inc. (VKTX) stock FAQ — growth, dividends, profitability & financials explained
Viking Therapeutics, Inc. (VKTX) reported a net loss of $472.3M for fiscal year 2025.
Viking Therapeutics, Inc. (VKTX) has a return on equity (ROE) of -47.3%. Negative ROE indicates the company is unprofitable.
Viking Therapeutics, Inc. (VKTX) had negative free cash flow of $340.3M in fiscal year 2025, likely due to heavy capital investments.
